ImmunoGen
Focusing on core therapeutic areas such as immunology, oncology, neuroscience, eye care, aesthetics, and other areas of unmet need.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A Valuation: $10.1b 92.8x EV/Revenue -46.4x EV/EBITDA | Acquisition | |
| Total Funding | 000k | ||
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (54 %) | 54 % | 61 % | (47 %) | 56 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (63 %) | (282 %) | (80 %) | (15 %) | (181 %) | (200 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (83 %) | (316 %) | (127 %) | (34 %) | (199 %) | (205 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 121 % | 326 % | 139 % | 87 % | 216 % | 196 % |
Source: Company filings or news article
Related Content
ImmunoGen, Inc. is a biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. ADCs are targeted therapies that combine the specificity of antibodies with the potency of cytotoxic drugs, aiming to deliver the drug directly to cancer cells while minimizing damage to healthy cells. The company operates in the oncology market, focusing on creating more effective and better-tolerated cancer therapies. ImmunoGen serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies. The business model is centered around research and development, clinical trials, and partnerships with other biotech firms and pharmaceutical companies. Revenue is generated through product sales, licensing agreements, and collaborations. ImmunoGen's innovative approach aims to raise the standards of cancer care and advance a dynamic oncology pipeline.
Keywords: antibody-drug conjugates, cancer treatment, biotechnology, oncology, targeted therapy, cytotoxic drugs, clinical trials, research and development, healthcare providers, pharmaceutical partnerships.